Vitamin D in Combination Cancer Treatment

Overview

Journal J Cancer

Specialty Oncology

Date 2010 Sep 16

PMID 20842231

Citations 43

Authors

Yingyu Ma

Donald L Trump

Candace S Johnson

Affiliations

Soon will be listed here.

Abstract

As a steroid hormone that regulates mineral homeostasis and bone metabolism, 1α, 25-dihydroxycholecalciferol (calcitriol) also has broad spectrum anti-tumor activities as supported by numerous epidemiological and experimental studies. Calcitriol potentiates the anti-tumor activities of multiple chemotherapeutics agents including DNA-damaging agents cisplatin, carboplatin and doxorubicin; antimetabolites 5-fluorouracil, cytarabine, hydroxyurea, cytarabine and gemcitabine; and microtubule-disturbing agents paclitaxel and docetaxel. Calcitriol elicits anti-tumor effects mainly through the induction of cancer cell apoptosis, cell cycle arrest, differentiation, angiogenesis and the inhibition of cell invasiveness by a number of mechanisms. Calcitriol enhances the cytotoxic effects of gamma irradiation and certain antioxidants and naturally derived compounds. Inhibition of calcitriol metabolism by 24-hydroxylase promotes growth inhibition effect of calcitriol. Calcitriol has been used in a number of clinical trials and it is important to note that sufficient dose and exposure to calcitriol is critical to achieve anti-tumor effect. Several trials have demonstrated that safe and feasible to administer high doses of calcitriol through intermittent regimen. Further well designed clinical trials should be conducted to better understand the role of calcitriol in cancer therapy.

Citing Articles

The therapeutic potential of 1, 25-dihydroxy vitamin D3 on cisplatin-affected neurological functions is associated with the regulation of oxidative stress and inflammatory markers as well as levels of MMP2/9.

Niapour A, Abdollahzadeh M, Ghaheri Fard S, Saadati H Metab Brain Dis. 2024; 39(6):1189-1200.

PMID: 39017968 DOI: 10.1007/s11011-024-01382-z.

EB1089 Increases the Antiproliferative Response of Lapatinib in Combination with Antiestrogens in HER2-Positive Breast Cancer Cells.

Achounna A, Ordaz-Rosado D, Garcia-Quiroz J, Morales-Guadarrama G, Milo-Rocha E, Larrea F Int J Mol Sci. 2024; 25(6).

PMID: 38542136 PMC: 10970597. DOI: 10.3390/ijms25063165.

Vitamin D in Cutaneous T-Cell Lymphoma.

Odum A, Geisler C Cells. 2024; 13(6.

PMID: 38534347 PMC: 10969440. DOI: 10.3390/cells13060503.

Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy?.

Riondino S, Formica V, Valenzi E, Morelli C, Flaminio V, Portarena I Curr Oncol. 2023; 30(1):1220-1231.

PMID: 36661743 PMC: 9857850. DOI: 10.3390/curroncol30010094.

Is Season of Diagnosis a Predictor of Cancer Survival? Results from the Zurich Cancer Registry.

Hysaj O, Karavasiloglou N, Limam M, Wanner M, Korol D, Rohrmann S Nutrients. 2022; 14(20).

PMID: 36296975 PMC: 9608958. DOI: 10.3390/nu14204291.

References

Marchionatti A, Picotto G, Narvaez C, Welsh J, Tolosa de Talamoni N . Antiproliferative action of menadione and 1,25(OH)2D3 on breast cancer cells. J Steroid Biochem Mol Biol. 2009; 113(3-5):227-32. DOI: 10.1016/j.jsbmb.2009.01.004. View

Moffatt K, Johannes W, Miller G . 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res. 1999; 5(3):695-703. View

Dunlap N, Schwartz G, Eads D, Cramer S, Sherk A, John V . 1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br J Cancer. 2003; 89(4):746-53. PMC: 2376931. DOI: 10.1038/sj.bjc.6601161. View

Jamshidi F, Zhang J, Harrison J, Wang X, Studzinski G . Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling. Cell Cycle. 2008; 7(7):917-24. PMC: 2843692. DOI: 10.4161/cc.7.7.5620. View

Beer T, Javle M, Ryan C, Garzotto M, Lam G, Wong A . Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol. 2006; 59(5):581-7. DOI: 10.1007/s00280-006-0299-1. View

Trump D, Deeb K, Johnson C . Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010; 16(1):1-9. PMC: 2857702. DOI: 10.1097/PPO.0b013e3181c51ee6. View

Ng K, Meyerhardt J, Wu K, Feskanich D, Hollis B, Giovannucci E . Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol. 2008; 26(18):2984-91. DOI: 10.1200/JCO.2007.15.1027. View

Danilenko M, Wang Q, Wang X, Levy J, Sharoni Y, Studzinski G . Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1alpha,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Res. 2003; 63(6):1325-32. View

Norman A, Mizwicki M, Norman D . Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov. 2004; 3(1):27-41. DOI: 10.1038/nrd1283. View

10.

Wu W, Zanello L, Walker A . S179D prolactin sensitizes human prostate cancer cells such that physiological concentrations of 1, 25 dihydroxy vitamin D3 result in growth inhibition and cell death. Prostate. 2007; 67(14):1498-506. DOI: 10.1002/pros.20598. View

11.

Ferrero D, Campa E, Dellacasa C, Campana S, Foli C, Boccadoro M . Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome. Haematologica. 2004; 89(5):619-20. View

12.

Rashid S, Moore J, Walker E, Driver P, Engel J, Edwards C . Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene. 2001; 20(15):1860-72. DOI: 10.1038/sj.onc.1204269. View

13.

Ly L, Zhao X, Holloway L, Feldman D . Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology. 1999; 140(5):2071-6. DOI: 10.1210/endo.140.5.6698. View

14.

Niitsu N, Umeda M, Honma Y . Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs. Leuk Res. 2000; 24(1):1-9. DOI: 10.1016/s0145-2126(99)00143-5. View

15.

Cohen S, Lippard S . Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001; 67:93-130. DOI: 10.1016/s0079-6603(01)67026-0. View

16.

Callens C, Coulon S, Naudin J, Radford-Weiss I, Boissel N, Raffoux E . Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010; 207(4):731-50. PMC: 2856037. DOI: 10.1084/jem.20091488. View

17.

Cicarma E, Tuorkey M, Juzeniene A, Ma L, Moan J . Calcitriol treatment improves methyl aminolaevulinate-based photodynamic therapy in human squamous cell carcinoma A431 cells. Br J Dermatol. 2009; 161(2):413-8. DOI: 10.1111/j.1365-2133.2009.09180.x. View

18.

Sutton A, MacDonald P . Vitamin D: more than a "bone-a-fide" hormone. Mol Endocrinol. 2003; 17(5):777-91. DOI: 10.1210/me.2002-0363. View

19.

Kim S, Cho S, Simkhada J, Lee H, Kim S, Kim T . Enhancement of 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced HL-60 leukemia cell differentiation by Panax ginseng. Biosci Biotechnol Biochem. 2009; 73(5):1048-53. DOI: 10.1271/bbb.80823. View

20.

Muindi J, Yu W, Ma Y, Engler K, Kong R, Trump D . CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology. 2010; 151(9):4301-12. PMC: 2940491. DOI: 10.1210/en.2009-1156. View